Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Oramed PharmaceuticalsORMP | Open-market buy | 23/04/03–23/04/04 | 23/04/04 | 8,809 sh2 trades | $2.22avg. | $19,517.98 | +48.9% | |
Nadav KidronPresident and CEO | Oramed PharmaceuticalsORMP | Open-market buy | 23/03/16 | 23/03/16 | 26,000 sh | $2.04 | $53,040 | +26.0% |
Nadav KidronPresident and CEO | Oramed PharmaceuticalsORMP | Open-market buy | 23/03/14 | 23/03/15 | 100,000 sh | $2.01 | $201,000 | No record |
Miriam KidronChief Scientific Officer | Oramed PharmaceuticalsORMP | Open-market sale | 23/03/14 | 23/03/15 | 100,000 sh | $2.01 | $201,000 | −33.1% |
Oramed PharmaceuticalsORMP | Open-market buy | 23/03/13–23/03/14 | 23/03/15 | 70,000 sh2 trades | $2.02avg. | $141,700 | +424.2% | |
Oramed PharmaceuticalsORMP | Open-market sale | 23/01/03 | 23/01/04 | 13,325 sh2 trades | $12.55avg. | $167,170.25 | −9.6% |